Nykode Therapeutics
Update in progressNYKD.OL (Oslo)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company that discovers and develops immunotherapies for cancer and autoimmune diseases. It develops vaccines for cancer, autoimmune, and infectious diseases. Its lead candidates are VB10.NEO, a cancer neoantigen vaccine in phase I/IIa for locally advanced or metastatic tumors, and VB10.16, a therapeutic vaccine in phase II for HPV-16–induced malignancies such as cervical cancer. Founded in 2006, based in Oslo, Norway.
Company score
- Sentiment
- -0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.43
- Governance
- -0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!